# Evaluation of Efficacy and Safety of Somatostatin Used as Inflow Modulator in Liver Transplantation.

> **NCT01290172** · PHASE1 · COMPLETED · sponsor: **University Hospital, Ghent** · enrollment: 33 (actual)

## Conditions studied

- Liver Transplant With Clinically Significant Portal Hypertension

## Interventions

- **DRUG:** Administration of Somatostatin
- **DRUG:** Administration of placebo

## Key facts

- **NCT ID:** NCT01290172
- **Lead sponsor:** University Hospital, Ghent
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2013-12
- **Final completion:** 2014-01
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2014-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01290172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01290172, "Evaluation of Efficacy and Safety of Somatostatin Used as Inflow Modulator in Liver Transplantation.". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT01290172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*